ZACKS RESEARCH

FUNDS

PORTFOLIO

BROKER RESEARCH

MARKETS

SCREENING

EDUCATION

SERVICES

Earnings

EPS Surprises

Mutual Funds

Options

My Account

Help

PeopleandPicks.com is Zacks' Community Website
Find great stocks and great stock pickers in our online community. It's social, it's profitable and it's Free! Join the fun at PeopleandPicks.com

Quote:

Search for Ticker

Free Membership

Search:

VRX: Valeant Pharmaceuticals Intl - Full Company Report Enter Ticker:

Quote	Estimates	Charts	Company Reports	News	Financials

Full Company Report \| Estimates \| Brokerage Recommendations \| Comparison to Industry \| Insiders \| Brokerage Reports \| Zacks Equity Research \| Annual Report

VALEANT PHARMACEUTICALS INTL (NYSE)
VRX	35.60	0.05	(0.14%)	Vol. 255,301	11:12 ET

Valeant Pharmaceuticals International is a global, publicly traded, research-based specialty pharmaceutical company that discovers, develops, manufactures and markets a broad range of pharmaceutical products.

General Information

VALEANT PHARMA

One Enterprise Aliso Viejo, CA 92656 Phone: 949 461-6000 Fax: 949-461-6609 Web: www.valeant.com Email: ir@icnpharm.com

Industry	MED-DRUGS
Sector:	Medical

Fiscal Year End	December
Last Reported Quarter	12/31/09
Next EPS Date	02/24/2010

Price and Volume Information

Zacks Rank
Yesterday's Close	35.55
52 Week High	36.02
52 Week Low	15.64
Beta	0.50
20 Day Moving Average	568,338.31
Target Price Consensus	36.25

% Price Change
4 Week	3.80
12 Week	3.77
YTD	11.83

% Price Change Relative to S&P 500
4 Week	10.17
12 Week	7.62
YTD	13.17

Share Information
Shares Outstanding (millions)	81.34
Market Capitalization (millions)	2,891.53
Short Ratio	9.64
Last Split Date	03/17/1998

Dividend Information
Dividend Yield	0.00%
Annual Dividend	$0.00
Payout Ratio	0.00
Change in Payout Ratio	0.00
Last Dividend Payout / Amount	NA / $0.00

EPS Information
Current Quarter EPS Consensus Estimate	0.58
Current Year EPS Consensus Estimate	2.14
Estimated Long-Term EPS Growth Rate	17.80
Next EPS Report Date	02/24/2010

Consensus Recommendations
Current (1=Strong Buy, 5=Strong Sell)	3.14
30 Days Ago	3.50
60 Days Ago	3.50
90 Days Ago	3.50

Fundamental Ratios

P/E
Current FY Estimate:	14.55
Trailing 12 Months:	17.17
PEG Ratio	0.82

EPS Growth
vs. Previous Year	427.27%
vs. Previous Quarter	13.73%

Sales Growth
vs. Previous Year	30.81%
vs. Previous Quarter:	14.93%

Price Ratios
Price/Book	8.58
Price/Cash Flow	20.96
Price / Sales	-

ROE
12/31/09	-
09/30/09	66.53
06/30/09	41.78

ROA
12/31/09	-
09/30/09	14.21
06/30/09	10.85

Current Ratio
12/31/09	-
09/30/09	1.58
06/30/09	2.87

Quick Ratio
12/31/09	-
09/30/09	1.35
06/30/09	2.53

Operating Margin
12/31/09	-
09/30/09	22.37
06/30/09	18.53

Net Margin
12/31/09	-
09/30/09	1.01
06/30/09	-6.80

Pre-Tax Margin
12/31/09	-
09/30/09	1.01
06/30/09	-6.80

Book Value
12/31/09	-
09/30/09	4.14
06/30/09	3.86

Inventory Turnover
12/31/09	-
09/30/09	1.83
06/30/09	1.80

Debt-to-Equity
12/31/09	-
09/30/09	1.64
06/30/09	2.05

Debt to Capital
12/31/09	-
09/30/09	62.07
06/30/09	67.20


About Zacks \| Advertise \| Affiliate \| Media \| Careers \| Contact Us \| Help Disclaimer \| Privacy Policy \| Sitemap NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed. Copyright 2010 Zacks Investment Research